Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06187480
Other study ID # E-78017789-050.01.04-1638902
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date January 1, 2023

Study information

Verified date December 2023
Source Mersin University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to investigate the changes in cardiac functions, especially myocardial performance index (MPI), in patients who underwent parathyroidectomy for secondary hyperparathyroidism. Participants who underwent parathyroidectomy for secondary hyperparathyroidism between June 2010 and September 2021 were analyzed retrospectively. The participants were divided into two groups: those who underwent total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2). The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.


Description:

Patient selection The participants who developed secondary hyperparathyroidism after chronic renal failure and underwent subtotal/total parathyroidectomy in our hospital between June 2010 and September 2021 were analyzed with a single-center Nested case-control study design. Patients with a diagnosis of chronic renal failure, secondary hyperthyroidism after chronic renal failure, preoperative and postoperative laboratory tests, parathyroidectomy operation, and preoperative and postoperative 6-month transthoracic echocardiography (ECHO) were included in the study. Advanced-stage lung disease, atrial fibrillation, atrial and supraventricular tachycardia, extra ventricular beats, intraventricular conduction disorders, ventricular pacing, moderate to severe valve pathology, history of bypass surgery, poor image quality in transthoracic echocardiography as cardiac comorbidities Patients with disease and missing data were excluded from the study. Data collection Demographic data (age, gender), surgery (total/subtotal parathyroidectomy) preoperative and postoperative laboratory analyses, and ECHO reports of the patients were recorded. In laboratory values, glucose, hemoglobin, albumin, blood urea nitrogen (BUN), creatinine, calcium, phosphorus, and parathormone values were recorded. In ECHO reports, left ventricular end-diastolic diameter (cm), left ventricular end-systolic diameter (cm), left ventricular end-diastolic septum thickness (cm), left ventricular end-diastolic posterior wall thickness (cm), ejection fraction (%), fractional shortening, end-diastolic volume, end-systolic volume, ejection volume, isovolumetric relaxation time (IVRT), isovolumetric contraction time (IVCT), ejection time (ET) and myocardial performance index (MPI) data were recorded. Surgical Technique Patients resistant to calcimimetics and vitamin D analogs, patients with symptoms such as bone and joint pain, persistent itching, and muscle aches, and patients whose symptoms affect their quality of life are among the indications for surgery. In addition, parathyroidectomy was performed on patients with uncontrolled hyperphosphatemia, anemia hyporesponsive to erythropoietin therapy, hypercalcemia, and vascular and tissue calcifications, considered complications of SHPT. Subtotal or total parathyroidectomy is performed in the SHPT. Total parathyroidectomy was performed without autotransplantation to prevent recurrent resistant SHPT in patients with long life expectancy and little or no possibility of kidney transplantation. In the preoperative period, routine ultrasound and 99mTc-sestamibi scintigraphy were performed on the patients. During neck exploration, tissues considered the parathyroid gland were examined as a frozen section. As a result of the frozen section, it was confirmed how many glands were removed. After parathyroidectomy was completed, intraoperative parathormone testing was performed in all patients, and it was observed that parathormone levels decreased. In the subtotal parathyroidectomy procedure, four parathyroid glands are explored. Usually, half of the parathyroid gland, closest to normal in appearance and size, is left in place with its vascular network. Other glands are excised. In the total parathyroidectomy procedure, four parathyroid glands are explored and excised. Then, a part of the parathyroid gland closest to normal in appearance and size is auto-transplanted into the sternoclaidomastoid muscle or the forearm. The transplantation area is marked with a metal clip. Echocardiography (ECHO) All patients were evaluated with two-dimensional, pulse-wave Doppler and tissue Doppler echocardiography. Philips HD11 XE device was used to detect echocardiographic data. Parasternal long axis view with M-Mode echocardiography method left ventricular interventricular septum thickness, left ventricular posterior wall thickness, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular end-diastolic volume, left ventricular end-systolic volume, left ventricular end-systolic volume, and fractional shortening data were determined. In addition, left ventricular stroke volume was determined by subtracting the left ventricular end-systolic volume from the left ventricular end-diastolic volume. Myocardial performance index calculation technique The myocardial performance index (MPI) is a numerical value obtained using cardiac time intervals. This numerical value was obtained by dividing the sum of isovolumetric contraction time (ICT) and isovolumetric relaxation time (IRT) by ejection time (ET). MPI can be detected using conventional Pulse-wave Doppler or tissue Doppler echocardiography. The mean average left ventricular (LV) MPI value is 0.39 ± 0.05. In adults, LV MPI values less than 0.40 are considered normal. Higher index values are associated with cardiac dysfunction. Our study obtained cardiac time intervals using Pulsed wave Doppler echocardiography techniques. MPI, Pulsed wave Doppler echocardiography from the apical four-chamber images, by placing the sample volume at the endpoints of the mitral valves, the time interval between the end and the beginning of the mitral flow (a), switching to the apical five-chamber images and placing the sample volume in the left ventricular outflow tract just below the aortic valves to determine the left ventricular ET (b) was done. The left ventricular isovolumetric (ICT+IRT) sum was calculated by subtracting left ventricular ET from the time interval between the end and beginning of mitral flow (a-b). Thus, MPI [(a-b)/b] was obtained. Statistical analysis Mean and standard deviation were used for the statistics of continuous data. Median, minimum, and maximum values were used for continuous or ordinal data that did not show normal distribution. Frequency (n) and percentage (%) values were used to define categorical variables. Fisher's exact test was used to compare the means of two independent groups. The chi-square test was used to evaluate the relationship between categorical variables. Paired t-test was used to compare the patient's preoperative and postoperative numerical data. The statistical significance level of the data was taken as p<0.05. The statistical program www.e-picos.com was used to evaluate the data.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date January 1, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with a diagnosis of chronic renal failure, secondary hyperthyroidism after chronic renal failure, preoperative and postoperative laboratory tests, parathyroidectomy operation, and preoperative and postoperative 6-month transthoracic echocardiography (ECHO) were included in the study. Exclusion Criteria: - Advanced-stage lung disease, atrial fibrillation, atrial and supraventricular tachycardia, extra ventricular beats, intraventricular conduction disorders, ventricular pacing, moderate to severe valve pathology, history of bypass surgery, poor image quality in transthoracic echocardiography as cardiac comorbidities Patients with disease and missing data were excluded from the study.

Study Design


Intervention

Procedure:
total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)
The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.

Locations

Country Name City State
Turkey Mersin University Faculty of Medicine Mersin

Sponsors (1)

Lead Sponsor Collaborator
Mersin University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of myocardial performance indexes between groups Evaluation of patients' myocardial performance indexes between groups using echocardiography and Doppler imaging in the preoperative period and at the 6th postoperative month. preoperatively and postoperative 6th month
See also
  Status Clinical Trial Phase
Completed NCT02549417 - Phase 3 Study of KHK7580 Phase 3
Completed NCT02549404 - Phase 3 Study of KHK7580 Phase 3
Completed NCT02549391 - Phase 3 Study of KHK7580 Phase 2/Phase 3
Not yet recruiting NCT02536287 - Comparison of Total Parathyroidectomy With and Without Autotransplantation Phase 3
Active, not recruiting NCT03023748 - Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase 4
Withdrawn NCT01426724 - Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease N/A
Completed NCT01101113 - Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Phase 4
Completed NCT01220050 - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism Phase 2
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT00431496 - A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Phase 4
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00117052 - SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Phase 3
Completed NCT00073710 - Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Phase 4
Completed NCT03626948 - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Phase 3
Completed NCT01382212 - A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis Phase 3
Completed NCT01219855 - Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Phase 2/Phase 3
Completed NCT01224782 - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) N/A
Completed NCT00990704 - Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism Phase 2
Completed NCT00999037 - FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease N/A
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2